Tonghua Dongbao Pharmaceutical (600867.SH) has repurchased a cumulative 1.17% of its shares, completing the second phase of its share repurchase plan.

Tonghua Dongbao Pharmaceutical (600867.SH) announced that by December 31, 2024, the company will complete 2024...

Zhitong FinanceJan 2 04:25 ET

Express News | Adocia SA - Phase 3 Topline Results Expected in H1 2025

ReutersDec 12, 2024 12:01 ET

ADOCIA and Tonghua Dongbao Announce the Final Dosing in a Phase 3 Clinical Study of BioChaperone Lispro, Milestone Associated With a $10 Million Payment

BusinesswireDec 12, 2024 12:00 ET

Tonghua Dongbao Pharmaceutical Co., Ltd.'s (SHSE:600867) Has Been On A Rise But Financial Prospects Look Weak: Is The Stock Overpriced?

Simply Wall StDec 12, 2024 01:07 ET

Tonghua Dongbao Pharmaceutical Completes Phase 1a Trial for Diabetes Injection

MT NewswiresDec 9, 2024 05:08 ET

Tonghua Dongbao Pharmaceutical (600867.SH): The THDBH120 has received the summary report of phase I clinical trial, and the research results have reached the main endpoint objectives.

Tonghua Dongbao Pharmaceutical (600867.SH) issued a statement that its wholly-owned subsidiary Dongbao Zixing (Hangzhou) Biomedical Co., Ltd...

Zhitong FinanceDec 6, 2024 02:35 ET